ALZHEIMER’S DISEASE DIAGNOSTICS AND THERAPEUTICS MARKET ANALYSIS
Global Alzheimer’s disease Diagnostics and Therapeutics Market: Key Developments
In October 2021, Salk Institute, a research institute in California, U.S., initiated a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to evaluate its safety in humans.
Moreover, In June, 2021, Biogen, a multinational biotechnology company, and Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., announced a range of programs/initiatives intended to support access for all qualified patients, including traditionally underserved populations
Alzheimer’s Disease Diagnostics and Therapeutics Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request DiscountPress Release
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :